Cargando…

Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study

BACKGROUND: Little is known about the impact of the dopamine system on development of cognitive impairment (CI) in Parkinson disease (PD). OBJECTIVES: We used data from a multi‐site, international, prospective cohort study to explore the impact of dopamine system‐related biomarkers on CI in PD. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weintraub, Daniel, Picillo, Marina, Cho, Hyunkeun Ryan, Caspell‐Garcia, Chelsea, Blauwendraat, Cornelis, Brown, Ethan G., Chahine, Lana M., Coffey, Christopher S., Dobkin, Roseanne D., Foroud, Tatiana, Galasko, Doug, Kieburtz, Karl, Marek, Kenneth, Merchant, Kalpana, Mollenhauer, Brit, Poston, Kathleen L., Simuni, Tanya, Siderowf, Andrew, Singleton, Andrew, Seibyl, John, Tanner, Caroline M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272925/ https://www.ncbi.nlm.nih.gov/pubmed/37332638 http://dx.doi.org/10.1002/mdc3.13751

Ejemplares similares

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression
por: Brumm, Michael C., et al.
Publicado: (2023)

Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort
por: Marek, Kenneth, et al.
Publicado: (2018)

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder
por: Chahine, Lana M., et al.
Publicado: (2020)

Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2022)

Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease
por: Mollenhauer, Brit, et al.
Publicado: (2019)

Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
por: Chahine, Lana M., et al.
Publicado: (2019)

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts
por: Merchant, Kalpana M., et al.
Publicado: (2023)

Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson’s disease: the PPMI cohort
por: Simuni, Tanya, et al.
Publicado: (2018)

Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease
por: Irwin, David J., et al.
Publicado: (2020)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Proposal for a Biologic Staging System of Parkinson’s Disease
por: Chahine, Lana M., et al.
Publicado: (2023)

Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease
por: Kremer, Thomas, et al.
Publicado: (2021)

Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease
por: Weintraub, Daniel, et al.
Publicado: (2020)

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
por: Bartl, Michael, et al.
Publicado: (2021)

Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
por: Chahine, Lana M., et al.
Publicado: (2018)

Predictors of time to initiation of symptomatic therapy in early Parkinson's disease
por: Simuni, Tanya, et al.
Publicado: (2016)

Cognition among individuals along a spectrum of increased risk for Parkinson’s disease
por: Chahine, Lana M., et al.
Publicado: (2018)

Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients
por: Alcalay, Roy N., et al.
Publicado: (2020)

Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
por: Caspell-Garcia, Chelsea, et al.
Publicado: (2017)

A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations
por: Mollenhauer, Brit, et al.
Publicado: (2017)

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease
por: Picillo, Marina, et al.
Publicado: (2022)

Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience
por: Dobkin, Roseanne D., et al.
Publicado: (2020)

In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease
por: Chahine, Lana M., et al.
Publicado: (2020)

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older
por: Brumm, Michael C., et al.
Publicado: (2023)

Deep Learning for Daily Monitoring of Parkinson’s Disease Outside the Clinic Using Wearable Sensors
por: Atri, Roozbeh, et al.
Publicado: (2022)

Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person
por: Chahine, Lana M., et al.
Publicado: (2020)

Status of Current Biofluid Biomarkers in Parkinson's Disease
por: Mollenhauer, Brit
Publicado: (2023)

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder
por: Chahine, L. M., et al.
Publicado: (2019)

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial
por: Simuni, Tanya, et al.
Publicado: (2020)

Biomarkers in biological fluids for dementia with Lewy bodies
por: Schade, Sebastian, et al.
Publicado: (2014)

Central and peripheral α‐synuclein in Parkinson disease detected by seed amplification assay
por: Chahine, Lana M., et al.
Publicado: (2023)

A proteogenomic view of Parkinson’s disease causality and heterogeneity
por: Kaiser, Sergio, et al.
Publicado: (2023)

Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression
por: Pereira, Joana B., et al.
Publicado: (2019)

Telephone-based cognitive behavioral therapy for depression in Parkinson disease: A randomized controlled trial
por: Dobkin, Roseanne D., et al.
Publicado: (2020)

Analysis of rare Parkinson’s disease variants in millions of people
por: Pitz, Vanessa, et al.
Publicado: (2023)

The REM Sleep Behavior Disorder Screening Questionnaire is not Valid in De Novo Parkinson's Disease
por: Halsband, Claire, et al.
Publicado: (2018)

Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression
por: Concha‐Marambio, Luis, et al.
Publicado: (2021)

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease
por: Eidson, Lori N., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ahnrcdkd1697kg10vdfolq0vdv